Drug Sponsors

NIH funds seven international centers of excellence for Malaria research

Monday, April 24, 2017

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, announced approximately $9 million in first-year funding, subject to availability, for seven malaria research centers around the world. The seven-year awards continue NIAID’s 2010 program that created the International Centers of Excellence for Malaria Research (ICEMRs) in regions where malaria is endemic. The awards fund three new and four existing centers that work in 14 countries in Africa, Asia and Latin America.

[Read More]

VolitionRX opens new R&D facility in Belgium

Monday, April 24, 2017

VolitionRx opened its new R&D facility. The new building will enable the company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other biotech and pharmaceutical companies.

[Read More]

Cardinal Health to acquire Medtronic Patient Product Portfolio

Thursday, April 20, 2017

Cardinal Health has entered into a definitive agreement to acquire Medtronic‘s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash. The purchase price does not include cash tax benefits of at least $100 million. The acquisition is expected to be financed with a combination of $4.5 billion in new senior unsecured notes and existing cash. The transaction is expected to close in the first quarter of Cardinal Health’s fiscal year 2018, subject to customary closing conditions, including regulatory clearances.

[Read More]

BioMed Realty invests in expanded research facilities at the Babraham Research Campus

Thursday, April 20, 2017

The Biotechnology and Biological Sciences Research Council (BBSRC), Babraham Bioscience Technologies (BBT) and BioMed Realty, a Blackstone portfolio company, have announced a partnership that will see BioMed Realty signing a long-term lease on approximately eight acres of BBSRC-owned land at the Babraham Research Campus, Cambridge, U.K. The investment will enable the ground-up construction of two new buildings for growing bioscience-based companies at the campus.

[Read More]

Nivalis Therapeutics, Alpine Immune Sciences to merge

Wednesday, April 19, 2017

Nivalis Therapeutics and Alpine Immune Sciences, a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology.

[Read More]

Breakout Labs funds four new companies

Friday, April 14, 2017

Breakout Labs, the Thiel Foundation’s seed-stage fund for deep technology companies, announced its latest four investments, each propelling radical science and technology to improve human health. The new awards bring the total number of companies backed by Breakout Labs to 34 since the program’s first investments in 2012.

[Read More]

BioMed Realty, UCSD to develop global center for oncology research

Tuesday, April 11, 2017

BioMed Realty, a Blackstone Real Estate company, and the University of California San Diego announced a new development known as the Center for Novel Therapeutics. The project will be home to university and local research organizations focused on finding critical treatments and potential cures for cancer and other chronic diseases. This new building will be centered in the university’s Science Research Park near Moores Cancer Center at UC San Diego Health.

[Read More]

Takeda announces Takeda-PRA Development Center KK

Tuesday, April 11, 2017

Takeda Pharmaceutical has entered into an agreement for absorption-type company split with its wholly-owned subsidiary which was established in March 2017 (NewCo) and intends to enter into another agreement for joint venture with Pharm Research Associates (PRA(UK)), a subsidiary of PRA Health Sciences, aiming for transferring a part of Takeda Development Center Japan (TDC Japan) businesses to PRA. Takeda and PRA announced the expansion of their partnership to Japan on February 15, 2017.

[Read More]

Sartorius acquires Umetrics, closes acquisition of Essen BioScience

Tuesday, April 11, 2017

Sartorius, an international partner of the biopharmaceutical industry and research laboratories, acquired through its subgroup Sartorius Stedim Biotech the company MKS Instruments (Umetrics) based in Malmö, Sweden. Umetrics is a specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. Umetrics has already been cooperating with Sartorius for around five years and, in 2017, plans to generate full-year sales revenue of around U.S. $15 million and a significant double-digit operating profit margin. Sartorius purchased the company for U.S. $72.5 million from the U.S. MKS Instruments Group.

[Read More]